Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 6/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14480015 | 1.00 | DPP4 (0.40) | DPP4HSD17B10LMNACYP2C19FAP | |
| SCHEMBL1920132 | 1.00 | DPP4 (0.40) | DPP4HSD17B10LMNACYP2C19FAP | |
| SCHEMBL2430899 | 1.00 | DPP4 (0.40) | DPP4HSD17B10LMNACYP2C19FAP | |
| SCHEMBL2330612 | 0.95 | HPGD (0.38) | DPP4HSD17B10LMNACYP2C19FAP | |
| SCHEMBL16600622 | 0.89 | DPP4 (0.34) | DPP4HSD17B10LMNACYP2C19RIPK1 | |
| SCHEMBL322779 | 0.89 | DPP4 (0.34) | DPP4HSD17B10LMNACYP2C19RIPK1 | |
| SCHEMBL4523902 | 0.89 | DPP4 (0.34) | DPP4HSD17B10LMNACYP2C19RIPK1 | |
| SCHEMBL322778 | 0.89 | DPP4 (0.34) | DPP4HSD17B10LMNACYP2C19RIPK1 | |
| Hydrochloric Acid SCHEMBL7517295 | 0.87 | DPP4 (0.33) | DPP4LMNARIPK1 | |
| SCHEMBL29392820 | 0.85 | DPP4 (0.40) | DPP4HSD17B10LMNACYP2C19FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432280-B2 | 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2008-10-07 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20070066663-A1 | 3-Aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1638560-A1 | 3-AMINOPIPERIDINES AND 3-AMINOQUINUCLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000305-A1 | 3-AMINOPIPERIDINES AND 3-AMINOQUINUCLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | DPP4 1811/4885HSD17B10 4475/4885LMNA 3437/4885 |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | DPP4 1425/4885HSD17B10 2316/4885LMNA 3228/4885 |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | DPP4 1289/4885HSD17B10 1573/4885LMNA 983/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | DPP4 2414/4885HSD17B10 2214/4885LMNA 2185/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | DPP4 2063/4885HSD17B10 1037/4885LMNA 3631/4885 |
| US-20070066663-A1 | 3-Aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A1 | DPP4 921/4885HSD17B10 1338/4885LMNA 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.